人民财讯1月9日电，华兰股份（301093）1月9日公告，公司于近日与宁波广峰胶囊有限公司(简称"广峰 胶囊")、宁波斯普康生物技术有限公司("转让方")签署了《关于宁波广峰胶囊有限公司之股份转让协 议》。本次华兰股份将使用846.47万元购买宁波斯普康在广峰胶囊持有的35%股权。交易完成后，华兰 股份持有广峰胶囊35%股权，在2026年至2028年期间，华兰股份有权根据协议约定进一步收购广峰胶囊 16%至35%的股权，届时持股比例将提升至51%至70%，从而实现对广峰胶囊的控股。广峰胶囊主营业 务为空心胶囊(属于药用辅料)的制造与销售。 ...

这份终裁对国内药用辅料龙头山东赫达而言意义非凡。作为强制应诉企业，公司反倾销税率从初裁的172.24%骤降至18.71%，降幅达153.53个百分点；反补 贴税率终裁为6.90%。税率的大幅回落不仅意味着对美出口竞争力的恢复，更释放出前期按高税率预缴的巨额保证金差额将获退还的实质性利好。12月22 日，山东赫达应声涨停，报收14.59元/股，今日盘中，山东赫达持续走高，截至发稿前封板涨停。 【文/王力 编辑/周远方】 历经13个月的跨国贸易角力，中国硬壳胶囊企业终于等来了转机。 12月19日，美国商务部对进口自中国、巴西、印度和越南的硬质空心胶囊作出反倾销和反补贴终裁，中国生产商获裁的倾销税率为0至18.71%，不仅远低于 巴西的77.63%和越南的47.12%，更较今年5月初裁时的惩罚性税率大幅下降。 回溯这场调查，2024年11月13日美国商务部正式立案时，山东赫达对美硬壳胶囊出口额占该产品总收入的62.38%，美国市场的得失直接关乎公司命脉。初 裁阶段172.24%的惩罚性税率曾令市场一度悲观，但公司积极应诉、据理力争，最终在终裁中实现逆转。 不过，这场贸易战役尚未完全画上句号。美国国际贸易委员会将于2 ...

Core Points - The company reported a revenue of 697 million yuan for the first three quarters of 2025, representing a year-on-year growth of 8.09% [1] - The net profit attributable to shareholders for the same period was 133 million yuan, with a year-on-year increase of 8.28% [1] - In the third quarter alone, the company achieved a revenue of 226 million yuan, marking a year-on-year growth of 16.06% [1] - The net profit for the third quarter was approximately 39.53 million yuan, showing a significant year-on-year increase of 46.99% [1]

Core Viewpoint - The company Erkang Pharmaceutical (300267) showcases its strengths and development potential in the pharmaceutical excipients industry during the 2025 Hunan Listed Companies Collective Reception Day and Semi-Annual Performance Briefing held on September 19. Group 1: Company Strengths - The company offers a diverse range of products, with 127 pharmaceutical excipient varieties, accounting for 32.87% of the 387 varieties listed in the 2025 edition of the Chinese Pharmacopoeia, covering nearly all commonly used pharmaceutical excipients [1] - Established supply relationships with over 3,000 domestic downstream customers, indicating high product and customer stickiness [1] - Possesses three significant research platforms: the "National Pharmaceutical Excipients Engineering Technology Research Center," the "National Recognized Enterprise Technology Center," and the "Key Laboratory of Pharmaceutical Excipients Engineering Technology of the National Medical Products Administration" [1] - Actively participates in the formulation and revision of standards for pharmaceutical excipients in the Chinese Pharmacopoeia and contributes to the compilation of the "Infrared Spectrum Collection of Pharmaceutical Excipients" [1] - Awarded the qualification of "Variety Guardian" for 12 types of pharmaceutical excipients by the National Pharmacopoeia Committee [1] - Achievements in quality improvement research for injectable pharmaceutical excipients, with the project "Key Technology Development and Industrialization of Injectable Pharmaceutical Excipients" winning the second prize in Hunan Province's Science and Technology Progress Award [1] - The company's starch capsules and other varieties have been included in the list of key varieties in the biopharmaceutical industry chain published by the Hunan Provincial Department of Industry and Information Technology (second batch) [1]

Core Viewpoint - The passing of Yin Zhenglong, the controlling shareholder and chairman of Anhui Shanhe Pharmaceutical Auxiliary Co., Ltd., is a significant event for the company, which may lead to changes in leadership but is not expected to disrupt its operations [1][3]. Group 1: Company Leadership - Yin Zhenglong passed away on August 26, 2025, at the age of 60, and had been the chairman and general manager since the company's inception [3][5]. - He held 63,057,454 shares, representing 26.90% of the total shares, making him the controlling shareholder [3]. - The company announced that the board's functionality will remain intact, and the management team will continue its operations without interruption [3]. Group 2: Company Operations - Following Yin Zhenglong's death, the company will conduct a board election to fill the chairman position, with current director and general manager Song Daocai temporarily assuming the role [3][5]. - The company reported a revenue of 471 million yuan for the first half of 2025, a year-on-year increase of 4.65%, while the net profit attributable to shareholders was approximately 93 million yuan, a decrease of 2.61% [8]. - Basic earnings per share were reported at 0.40 yuan, down 2.44% year-on-year [8]. Group 3: Company Background - Anhui Shanhe Pharmaceutical Auxiliary Co., Ltd. was established in April 2001 and specializes in the production, research, and sales of new pharmaceutical excipients, holding a leading position in the domestic market [8]. - The company was listed on the Shenzhen Stock Exchange's Growth Enterprise Market in May 2015 [8]. Group 4: Recent Developments - The company's official website has been changed to a black-and-white page, indicating a period of mourning [6]. - Yin Zhenglong had recently chaired a shareholders' meeting on August 18 and a board meeting on the morning of August 26, just hours before his passing [5].

Core Viewpoint - The chairman and actual controller of Shanhe Pharmaceutical Excipients, Yin Zhenglong, passed away at the age of 60, leading to a significant impact on the company's stock price and governance structure [1][3]. Company Overview - Shanhe Pharmaceutical Excipients is engaged in the research, production, and sales of pharmaceutical excipients, with main products including fillers, adhesives, disintegrants, lubricants, and coating materials for oral solid dosage forms and injectable pharmaceutical excipients [2]. Impact of Chairman's Death - Following the announcement of the chairman's death, the company's stock price fell over 4%, closing at 13.64 yuan per share [3]. - The company’s official website has been changed to black and white as a sign of mourning [3]. - Yin Zhenglong was the founder and had served as chairman and general manager since the company's inception, playing a crucial role in its growth and listing on the Shenzhen Stock Exchange [3]. - He held 63,057,454 shares, representing 26.90% of the total shares, making him the controlling shareholder [3]. Governance Transition - The company announced that it will promptly complete the election of a new chairman according to relevant laws and regulations [3]. - In the interim, the current director and general manager, Song Daocai, will assume the responsibilities of chairman and legal representative until a new chairman is elected [3].

Core Points - The chairman and actual controller of the company, Yin Zhenglong, passed away on August 26, 2025, at the age of 60 [1][3] - Yin Zhenglong was the founder of the company and held 63,057,454 shares, accounting for 26.90% of the total shares, making him the controlling shareholder [3] - Following his passing, the board of directors appointed Song Daocai, a director and general manager, to temporarily assume the roles of chairman and legal representative until a new chairman is elected [3] - The company specializes in the research, production, and sales of pharmaceutical excipients, including fillers, adhesives, disintegrants, lubricants, and coating materials for oral solid dosage forms [3] - The company's official website turned black and white on August 27, 2025, in tribute to the deceased chairman [3]

Core Viewpoint - The sudden passing of Mr. Yin Zhenglong, the controlling shareholder, actual controller, and chairman of the company, has raised concerns about the future leadership and management of the company [1][3]. Company Overview - Anhui Shanhe Pharmaceutical Excipients Co., Ltd. was established in April 2001 and specializes in the production, research and development, and sales of new pharmaceutical excipients [6]. - The company is a leading player in the domestic pharmaceutical excipients (solid preparations) industry and was listed on the Shenzhen Stock Exchange's Growth Enterprise Market in May 2015 under the stock code 300452 [6]. - The company has a registered capital of 180.46707 million RMB and operates subsidiaries including Qufu Tianli Pharmaceutical Excipients Co., Ltd. (controlling) and Hefei Shanhe Pharmaceutical Technology Co., Ltd. (wholly-owned) [6]. Leadership Transition - Mr. Yin Zhenglong held 63,057,454 shares, accounting for 26.90% of the company's total shares, making him the controlling shareholder and actual controller [3]. - Following Mr. Yin's passing, the company announced that the board of directors would not fall below the legal number of members, ensuring normal operations [3]. - The company’s management team will continue to perform their duties, and the board will expedite the election of a new chairman [3]. - Mr. Song Daocai, a board member and general manager, has been temporarily appointed to fulfill the duties of chairman and legal representative until a new chairman is elected [3].

Core Points - The chairman and actual controller of the company, Yin Zhenglong, passed away on August 26, 2025, at the age of 60 [1][3] - Yin Zhenglong was the founder of the company and had held key positions since its establishment, including chairman and general manager [3] - He owned 63.0575 million shares, accounting for 26.9% of the total shares, making him the controlling shareholder [3] - The company will handle the transfer of shares according to relevant laws and regulations and will disclose information as necessary [3] - The board of directors has appointed Song Daocai, a director and general manager, to temporarily assume the roles of chairman and legal representative until a new chairman is elected [3] - The company specializes in the research, production, and sales of pharmaceutical excipients, including fillers, adhesives, disintegrants, lubricants, and coating materials for oral solid dosage forms [3] - As of August 26, 2025, the company's stock price was 14.34 yuan per share, with a total market capitalization of 3.4 billion yuan [3] - The number of shareholders as of June 30, 2025, was 17,500 [3]

Core Viewpoint - The passing of Yin Zhenglong, the founder and chairman of Shanhe Pharmaceutical Excipients, marks a significant transition for the company, which has grown from a small local pharmaceutical factory to a leading player in the pharmaceutical excipients industry in China [1][2]. Company Overview - Shanhe Pharmaceutical Excipients was established in April 2001 and specializes in the production, research, and sales of new pharmaceutical excipients, becoming a private joint-stock enterprise [2]. - The company was listed on the Shenzhen Stock Exchange's Growth Enterprise Market in May 2015 [2]. Leadership Transition - Following the death of Yin Zhenglong on August 26, 2025, the company announced that Song Daocai, the current director and general manager, will temporarily assume the roles of chairman and legal representative until a new chairman is elected [3]. Financial Performance - For the first half of 2025, the company achieved a total operating revenue of 471 million yuan, representing a year-on-year increase of 4.65% [3]. - The net profit attributable to shareholders was approximately 93.04 million yuan, a decrease of 2.61% compared to the previous year [3]. - The net profit after deducting non-recurring gains and losses was about 84.75 million yuan, reflecting a year-on-year growth of 6.05% [3]. Industry Position - Shanhe Pharmaceutical Excipients has positioned itself as a leader in the pharmaceutical excipients sector, with over 170 projects supporting the localization of excipients [2]. - The company offers a wide range of products, including 46 CDE registered products and holds 22 national invention patents, with several core products achieving the highest market share domestically [2].